{"transactions":[{"id":717678,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-07-02T20:21:34.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":23696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units (\"RSU\") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027."}],"balance_after":23696,"source":{"system":"sec-edgar","filing":"0001401914-26-000036","document":"wk-form4_1783023690.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000036/wk-form4_1783023690.xml","form_type":"4"}},{"id":741489,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T21:03:40.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":10000,"derivative":{"exercise_price":2.03,"expiration_date":"2036-06-11","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001519612-26-000002","document":"wk-form4_1781211817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000151961226000002/wk-form4_1781211817.xml","form_type":"4"}},{"id":1089224,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-10T20:05:18.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":4500,"derivative":{"exercise_price":2.44,"expiration_date":"2035-07-09","underlying":"Common stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001401914-25-000036","document":"wk-form4_1752177909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191425000036/wk-form4_1752177909.xml","form_type":"4"}},{"id":1483075,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:46:18.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":14.91,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-072215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000095017024072215/ownership.xml","form_type":"4"}},{"id":1483074,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:46:18.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3269,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":21.27,"underlying":"Common Stock","underlying_shares":3269},"source":{"system":"sec-edgar","filing":"0000950170-24-072215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000095017024072215/ownership.xml","form_type":"4"}},{"id":1483073,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:46:18.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":13.98,"underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-072215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000095017024072215/ownership.xml","form_type":"4"}},{"id":1483072,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:46:18.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":8.27,"underlying":"Common Stock","underlying_shares":9570},"source":{"system":"sec-edgar","filing":"0000950170-24-072215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000095017024072215/ownership.xml","form_type":"4"}},{"id":1483071,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:46:18.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":22.49,"underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000950170-24-072215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000095017024072215/ownership.xml","form_type":"4"}},{"id":1486566,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:15:35.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.43,"expiration_date":"2034-06-05","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-24-023178","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224023178/ownership.xml","form_type":"4"}},{"id":1496367,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:38:32.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":36.55,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-24-000278","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000161071724000278/form4.xml","form_type":"4"}},{"id":1844911,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T20:05:17.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 21, 2024, subject to continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":14.91,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-039326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919123039326/doc4.xml","form_type":"4"}},{"id":1847699,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T01:41:31.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-06-21","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001401914-23-000030","document":"wk-form4_1687398083.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191423000030/wk-form4_1687398083.xml","form_type":"4"}},{"id":1860127,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:47:39.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":25.4,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-23-000114","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000161071723000114/form4.xml","form_type":"4"}},{"id":2050478,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T21:05:24.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":3269,"price":15.2952,"value":50000.0088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023."}],"balance_after":3269,"derivative":{"exercise_price":21.27,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":3269},"source":{"system":"sec-edgar","filing":"0001209191-23-003992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919123003992/doc4.xml","form_type":"4"}},{"id":2221831,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T20:05:36.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2023, subject to continued service through such date."}],"balance_after":18500,"derivative":{"exercise_price":13.98,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-039195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919122039195/doc4.xml","form_type":"4"}},{"id":2221922,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:03:59.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":38000,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-23","underlying":"Common stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001401914-22-000056","document":"wf-form4_165610102252631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000056/wf-form4_165610102252631.xml","form_type":"4"}},{"id":2235495,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T22:27:17.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.29,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-22-012699","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000156761922012699/doc1.xml","form_type":"4"}},{"id":2235492,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T22:25:42.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.29,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-22-012698","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000156761922012698/doc1.xml","form_type":"4"}},{"id":2429911,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-20T22:01:11.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":9570,"price":5.22,"value":49955.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy.  2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy.  2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022."}],"balance_after":9570,"derivative":{"exercise_price":8.27,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":9570},"source":{"system":"sec-edgar","filing":"0001209191-22-004084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919122004084/doc4.xml","form_type":"4"}},{"id":2654479,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T20:00:18.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in full on June 23, 2022, subject to continued service through such date."}],"balance_after":12000,"derivative":{"exercise_price":35.86,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-043267","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919121043267/doc4.xml","form_type":"4"}},{"id":2655732,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T20:51:10.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":30000,"derivative":{"exercise_price":1.46,"expiration_date":"2031-06-24","underlying":"Common stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001401914-21-000098","document":"wf-form4_162456781006637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191421000098/wf-form4_162456781006637.xml","form_type":"4"}},{"id":2853562,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-17T11:10:24.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":22000,"derivative":{"exercise_price":18.91,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001567619-21-004153","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000156761921004153/doc1.xml","form_type":"4"}},{"id":2853561,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-17T11:10:11.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":22000,"derivative":{"exercise_price":18.91,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001567619-21-004152","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000156761921004152/doc1.xml","form_type":"4"}},{"id":3080149,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-17T20:00:14.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":723,"price":34.58,"value":25001.34,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued upon election by the director to receive her cash board retainer fee for the second half of 2020 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy and 362 shares will vest on September 30, 2020 and 361 shares will vest on December 31, 2020, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company."}],"balance_after":723,"derivative":{"exercise_price":53.41,"expiration_date":"2030-07-15","underlying":"Common Stock","underlying_shares":723},"source":{"system":"sec-edgar","filing":"0001209191-20-042768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919120042768/doc4.xml","form_type":"4"}},{"id":3098390,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-27T00:55:00.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":22500,"derivative":{"exercise_price":1.03,"expiration_date":"2030-06-25","underlying":"Common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001401914-20-000093","document":"wf-form4_159321928214573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191420000093/wf-form4_159321928214573.xml","form_type":"4"}},{"id":3111476,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T20:00:15.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in full on June 10, 2021, subject to continued service through such date."}],"balance_after":12000,"derivative":{"exercise_price":56.46,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-036233","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919120036233/doc4.xml","form_type":"4"}},{"id":3309969,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":6.21,"expiration_date":"2029-05-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309968,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.23,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309967,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.68,"expiration_date":"2026-05-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309966,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.8,"expiration_date":"2025-05-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309965,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.42,"expiration_date":"2024-05-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309964,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.78,"expiration_date":"2023-05-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309963,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.82,"expiration_date":"2022-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309962,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":6.71,"expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309961,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":6.96,"expiration_date":"2021-04-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309960,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.48,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3309959,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:57.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":50000,"price":20,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004729","document":"tm203607d10_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004729/tm203607d10_4.xml","form_type":"4"}},{"id":3465721,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-08T22:31:27.000Z","date":"2019-07-08","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 36 equal monthly installments following the vesting commencement date of July 8, 2019, subject to continued service through such dates."}],"balance_after":24000,"derivative":{"exercise_price":22.49,"expiration_date":"2029-07-07","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-19-041483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1519612/000120919119041483/doc4.xml","form_type":"4"}},{"id":3489413,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T18:35:08.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":22500,"derivative":{"exercise_price":0.9,"expiration_date":"2029-06-13","underlying":"Common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001401914-19-000066","document":"wf-form4_156053729327372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191419000066/wf-form4_156053729327372.xml","form_type":"4"}},{"id":3526515,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options","published_at":"2019-05-15T12:22:43.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 1 year from date of grant."}],"balance_after":40000,"derivative":{"exercise_price":6.21,"expiration_date":"2029-05-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001019695-19-000019","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000101969519000019/primary_doc.xml","form_type":"4"}},{"id":3562576,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:12:05.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":1.31,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023683/doc4.xml","form_type":"4"}},{"id":3562575,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:12:05.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":4.05,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023683/doc4.xml","form_type":"4"}},{"id":3562574,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:12:05.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.  At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":5.6,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-023683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023683/doc4.xml","form_type":"4"}},{"id":3701863,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-07T20:15:38.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 3, 2020."}],"balance_after":12500,"derivative":{"exercise_price":1.31,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-002657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119002657/doc4.xml","form_type":"4"}},{"id":3869209,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-11T21:44:44.000Z","date":"2018-07-10","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 1/3rd of the shares subject to this option on each of July 10, 2019, 2020 and 2021, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":1.35,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-18-042384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000120919118042384/doc4.xml","form_type":"4"}},{"id":3939554,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options","published_at":"2018-05-10T12:16:30.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 1 year from the date of grant May 8, 2018."}],"balance_after":20000,"derivative":{"exercise_price":2.48,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001019695-18-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000101969518000002/primary_doc.xml","form_type":"4"}},{"id":4104192,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-08T20:33:55.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 4, 2019."}],"balance_after":12500,"derivative":{"exercise_price":4.05,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-002819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919118002819/doc4.xml","form_type":"4"}},{"id":4137790,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-12-08T21:07:18.000Z","date":"2017-07-19","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Dr. Kelley was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the \"Director Options\") pursuant to the Corporation's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Director Options will vest in full on the earlier of the one year anniversary of the date of grant or immediately prior to the Corporation's 2018 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This form amends a Form 4 previously filed for Dr. Kelley on July 21, 2017, to correct the description of the vesting schedule of the stock options."}],"balance_after":2000,"derivative":{"exercise_price":6.56,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-17-064686","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000120919117064686/doc4a.xml","form_type":"4/A","original_submission_date":"2017-07-21"}},{"id":4253197,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-07-21T21:21:00.000Z","date":"2017-07-19","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Dr. Kelley was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the \"Director Options\") pursuant to the Corporation's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Director Options will vest in equal annual installments over a three-year period measured from the date of grant, subject to Dr. Kelley's continued service to the Corporation and will become exercisable in full upon a change of control of the Corporation."}],"balance_after":2000,"derivative":{"exercise_price":6.56,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-17-046001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000120919117046001/doc4.xml","form_type":"4"}},{"id":4306915,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options","published_at":"2017-05-24T10:44:48.000Z","date":"2017-05-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest one year from the date of grant May 23, 2017."}],"balance_after":20000,"derivative":{"exercise_price":1.23,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001019695-17-000016","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000101969517000016/primary_doc.xml","form_type":"4"}},{"id":4496309,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":32782,"kind":"person","name":"Kelley Susan L.","position":1,"cik":"0001519612","reported_name":"Kelley Susan L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-06T21:04:36.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will become fully vested on January 4, 2018, subject to the Reporting Person's continuous service through such\ndate."}],"balance_after":10000,"derivative":{"exercise_price":5.6,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-002801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919117002801/doc4.xml","form_type":"4"}}]}